<DOC>
	<DOCNO>NCT02524678</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , PK PD URC102 healthy subject .</brief_summary>
	<brief_title>Phase 1 Study ( Additional ) URC102 Healthy Subjects</brief_title>
	<detailed_description>Tolerability , safety , pharmacokinetics ( PK ) URC102 assess 7-day repeated oral dose healthy adult Korean male . In addition , pharmacodynamic ( PD ) response blood urinary uric acid level assess .</detailed_description>
	<criteria>Healthy male volunteer Participated clinical study within past 3 month prior receive IP administration</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>